Next Article in Journal
The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists
Next Article in Special Issue
Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors
Previous Article in Journal / Special Issue
Interactions of a Dopamine D1 Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat
Open AccessReview

NMDA Receptor Antagonists for Treatment of Depression

1
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, PA 19104, USA
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Tandogan 06100, Ankara, Turkey
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(4), 480-499; https://doi.org/10.3390/ph6040480
Received: 31 January 2013 / Revised: 27 March 2013 / Accepted: 27 March 2013 / Published: 3 April 2013
(This article belongs to the Special Issue NMDA Receptor Antagonists for Treatment of CNS Disorders)
Depression is a psychiatric disorder that affects millions of people worldwide. Individuals battling this disorder commonly experience high rates of relapse, persistent residual symptoms, functional impairment, and diminished well-being. Medications have important utility in stabilizing moods and daily functions of many individuals. However, only one third of patients had considerable improvement with a standard antidepressant after 2 months and all patients had to deal with numerous side effects. The N-methyl-d-aspartate (NMDA) receptor family has received special attention because of its critical role in psychiatric disorders. Direct targeting of the NMDA receptor could result in more rapid antidepressant effects. Antidepressant-like effects of NMDA receptor antagonists have been demonstrated in different animal models. MK-801 (a use-dependent channel blocker), and CGP 37849 (an NMDA receptor antagonist) have shown antidepressant properties in preclinical studies, either alone or combined with traditional antidepressants. A recent development is use of ketamine clinically for refractory depression. The purpose of this review is to examine and analyze current literature on the role of NMDA receptor antagonists for treatment of depression and whether this is a feasible route in drug discovery. View Full-Text
Keywords: NMDA receptor antagonists; depression; antidepressant-like effect; ketamine; MK-801; forced swim test NMDA receptor antagonists; depression; antidepressant-like effect; ketamine; MK-801; forced swim test
Show Figures

Figure 1

MDPI and ACS Style

Ates-Alagoz, Z.; Adejare, A. NMDA Receptor Antagonists for Treatment of Depression. Pharmaceuticals 2013, 6, 480-499.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop